AbbVie Inc. (NYSE:ABBV)

CAPS Rating: 5 out of 5


Player Avatar cabostacos (41.52) Submitted: 1/8/2013 12:22:24 AM : Outperform Start Price: $31.95 ABBV Score: +69.23

They are the hands down frontrunner in regards to treating the genotype 1 hep c patients.gilead is painting a picture of big success but if you look deeper they are using geno 2 when in reality, the hard to treat prevelent geno 1 null responders are being sent home without SVR 1 in 10 clears

Member Avatar Robou812 (< 20) Submitted: 4/30/2013 4:50:40 PM
Recs: 0

I am currently enrolled in the stage III clinical trial (geno type 1), the results have been outstanding with very very minimal side effects, I am SVR 1 after 4 weeks, I did the only thing I could think of, I invested, As above Good Yield, lower PE relative to competitors, Respected Parent Corporate Culture, under the radar for now, when approval comes for the HPC this one is headed much much higher

Featured Broker Partners